Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00020969
Status:
TERMINATED
Last Update Posted:
2020-10-05
First Post:
2001-07-11
Brief Title:
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Sponsor:
CTI BioPharma
Organization:
CTI BioPharma
Conditions & Keywords Data
Conditions:
| Name |
|---|
| MyelodysplasticMyeloproliferative Neoplasms |
| Leukemia |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| myelodysplasticmyeloproliferative neoplasm unclassifiable | View |
| refractory anemia | View |
| refractory anemia with ringed sideroblasts | View |
| refractory anemia with excess blasts | View |
| refractory anemia with excess blasts in transformation | View |
| chronic myelomonocytic leukemia | View |
| de novo myelodysplastic syndromes | View |
| previously treated myelodysplastic syndromes | View |
| secondary myelodysplastic syndromes | View |
| atypical chronic myeloid leukemia BCR-ABL1 negative | View |